UPDATED: Biogen finally publishes PhIII results for Aduhelm as critics chastise low-ranking journal, ‘gentle and unrevealing’ peer review
Biogen quietly announced at a conference in Spain today that a manuscript of the Phase III results for the company’s controversial Alzheimer’s drug Aduhelm has finally been published in a tiny journal with a conflicted chief editor, almost a year after the drug won its accelerated approval.
The manuscript was published Wednesday in the Journal of Prevention of Alzheimer’s Disease, a spokesperson told Endpoints News, pointing to the release’s link to a company presentation today at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.